Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Deferred Tax Liability (2021 - 2024)

Xeris Biopharma Holdings (XERS) has disclosed Non-Current Deferred Tax Liability for 5 consecutive years, with $3.3 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Non-Current Deferred Tax Liability rose 16.92% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Jun 2024, up 16.92%, and an annual FY2023 reading of $20.5 million, up 481.72% over the prior year.
  • Non-Current Deferred Tax Liability was $3.3 million for Q2 2024 at Xeris Biopharma Holdings, up from $2.6 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $20.5 million in Q4 2023 and bottomed at $442000.0 in Q4 2020.
  • Average Non-Current Deferred Tax Liability over 5 years is $4.7 million, with a median of $3.5 million recorded in 2022.
  • The sharpest move saw Non-Current Deferred Tax Liability surged 1018.1% in 2021, then plummeted 35.06% in 2023.
  • Year by year, Non-Current Deferred Tax Liability stood at $442000.0 in 2020, then soared by 1018.1% to $4.9 million in 2021, then dropped by 28.81% to $3.5 million in 2022, then skyrocketed by 481.72% to $20.5 million in 2023, then plummeted by 83.76% to $3.3 million in 2024.
  • Business Quant data shows Non-Current Deferred Tax Liability for XERS at $3.3 million in Q2 2024, $2.6 million in Q1 2024, and $20.5 million in Q4 2023.